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Abstract Paraneoplastic cerebellar degeneration (PCD)
is often associated with Yo antibodies that are directed
against human cerebellar degeneration-related protein 2
(CDR2). Such antibodies may also be found in ovarian
cancer patients without PCD. We studied if there was an
association between Yo antibody production and differ-
ences in CDR2 cDNA sequence, mRNA or CDR2
expression in ovarian cancers. We found similar CDR2
cDNA sequence, mRNA and protein levels in primary
ovarian cancers, with or without associated Yo antibodies.
CDR2 was also present in other cancers, as well as in
normal ovary tissue. The results suggest that Yo antibodies
are not only related to the expression of CDR2 alone, but
also to immune dysregulation.
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Introduction
Paraneoplastic cerebellar degeneration (PCD) is often
related to breast and ovarian tumors, which aberrantly
express an onconeural antigen called cerebellar degenera-
tion-related protein 2 (CDR2) [1, 2]. Although CDR2 is a
widely expressed gene at the mRNA level, post-transcrip-
tional mechanisms have been reported to confine the
expression of CDR2 protein to mouse cerebellum and testis
[3]. CDR2 protein has been shown to be present in 62% of
ovarian cancers, but not in normal ovary tissue [4].
The biological function of CDR2 is partly characterized,
as CDR2 through its leucine zipper motif has been dem-
onstrated to interact with c-myc [5], with cell cycle-related
proteins [6, 7] and with a protein kinase [8], indicating that
CDR2 is involved in signal transduction and gene tran-
scription. Furthermore, CDR2 has been found to attenuate
hypoxic response in renal cell carcinoma [9], and recent
data suggest a role for CDR2 and c-myc in mitosis in
cycling cells [10].
Patients with PCD often harbor Yo antibodies and
CDR2-specific cytotoxic lymphocytes in the blood and
cerebrospinal fluid. It is, therefore, proposed that both
humoral and cellular immune mechanisms participate in
the pathogenesis of PCD, leading to necrosis or apoptosis
of Purkinje cells [1, 2, 11]. The role of Yo antibodies in
PCD is uncertain, as such antibodies are also observed in
cancer patients without paraneoplastic neurological syn-
dromes [12, 13]. Recently, Yo antibodies have been linked
to CCDC104 antibodies, but the function of CCDC104 is
largely unknown [14].
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How Yo antibody synthesis is regulated in some patients
with cancer is unknown. We have, therefore, studied
whether the production of Yo antibodies could be related to
variants in the CDR2-coding sequence or to differences in
the mRNA or protein levels of CDR2 in ovarian cancer.
Furthermore, as previous results have suggested that CDR2
is only present in ovarian cancers and not in normal ovary
tissue [4], we also studied whether there could be post-
transcriptional differences in such tissue.
Materials and methods
Tissue and serum samples
Ovarian cancers were obtained from 16 patients aged
41–79 years operated at the Department of Gynaecology,
Haukeland University Hospital (Table 1). None of the
patients received chemotherapy or immunotherapy before
the operation. Two of the patients had PCD. From these
two patients only formalin-fixed cancer tissue was avail-
able. Colon cancer was obtained from a patient without
paraneoplastic neurological syndrome. Normal human
cerebrum and cerebellum were obtained from autopsy of a
patient without neurological disorder. The following cancer
cell lines were obtained from ATCC (www.lgcstandards-
atcc.org): lung cancer (A549), ovarian cancer (SK-OV-3),
neuroblastoma (SK-N-SH), and cervical cancer (HeLa).
Tissue and cell lysates were made using total protein
extraction kit from Chemicon (www.chemicon.com).
Lysates from human ovary tumor and human normal ovary
tissue were purchased from Prosci Inc (www.prosci-
inc.com). Recombinant CDR2 protein was produced in a
coupled transcription/translation (ITT) system with a T7
RNA polymerase and nuclease-treated rabbit reticulocyte
lysate, and CDR2-negative lysate was prepared with the
ITT reaction without plasmid [12, 13]. Protein concentra-
tions were determined using a BioRad DC protein assay
(www.biorad.com). Tissue and lysates were kept at -80C
and serum samples at -20C. Yo antibodies have previ-
ously been found in 3 of 182 sera from patients
with ovarian cancer at the Department of Gynaecology,
Haukeland University Hospital, and the 14 patients inclu-
ded in this report were part of this study [13]. In addi-
tion, we also included two patients with PCD and Yo
antibodies.
RNA purification and cDNA synthesis
Total RNA was extracted from 14 ovarian cancers by
homogenization in a Trizol reagent (www.invitrogen.com)
and RTL buffer containing b-mercaptoethanol followed by
RNeasy mini-kit (www.qiagen.com). We also used a panel
of human total RNA from 11 different types of tissue
(brain, heart, kidney, liver, lung, trachea, mammary gland,
prostate, skeletal muscle, testis and uterus), as well as
human reference total RNA (www.clontech.com). RNA
was stored at -80C until use. From each of the samples,
we reverse transcribed 100 ng of RNA to cDNA using
TaqMan RT reagents according to the manufacturer’s
instructions (www.appliedbiosystems.com).
Table 1 Patients with ovarian
cancer and presence of Yo
antibodies and CDR2 mRNA
and protein
a Patients with paraneoplastic
cerebellar degeneration; CDR2
cerebellar degeneration-related
protein 2; FIGO International
Federation of Gynecology and
Obstetrics
Patient
no.
Age
(years)
Histology
(adenocarcinoma)
FIGO
stage
Yo
antibody
CDR2
mRNA
CDR2
protein
1 78 Endometrioid III ? ? ?
2 55 Serous III - ? ?
3 57 Serous III - ? ?
4 53 Mucinous/borderline III - ? ?
5 64 Serous III - ? ?
6 69 Undifferentiated III - ? ?
7 58 Serous IV ? ? ?
8 78 Serous IV - ? ?
9 56 Serous III - ? ?
10 48 Endometrioid III - ? ?
11 62 Endometrioid III ? ? ?
12 79 Mucinous I - ? ?
13 41 Mucinous/borderline I - ? ?
14 55 Clear cell I - ? ?
15a 60 Serous III ? ND ?
16a 58 Serous IV ? ND ?
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Real-time quantitative polymerase chain reaction
Real-time quantitative polymerase chain reaction (RT-
PCR) was used to quantify mRNA expression in the 14
ovarian cancers, the panel of human total RNA and the
human reference total RNA. All primers and probes were
obtained from Assay-on-Demand gene expression products
at Applied Biosystems (www.appliedbiosystems.com). As
endogenous control genes, we used human large ribosomal
protein (RPLPO), human transcription factor IID/TATA
box-binding protein (TBP) and the housekeeping gene
human glyceraldehyde phosphate dehydrogenase (GAP-
DH), including the test gene CDR2. We performed the RT-
PCR in the ABI prism 7900 Sequence Detection System
run by standard PCR cycling conditions. The relative
quantification of mRNA expression was based on the
standard curve method (User Bulletin #2, Applied Bio-
systems). Human reference total RNA (www.clontech.com)
was used to generate the standard curve. We included a
‘‘no template control’’ in each run. Each sample was run
and analyzed in triplicate.
The expression of CDR2 was normalized to all the three
reference genes (PO, TBP, and GAPDH). The data were
transferred to Graphpad Prism, version 3.0 (www.graph
pad.com) and calculated using Mann–Whitney nonpara-
metric U-test. P \ 0.05 was considered statistically
significant. We assessed the three reference genes to
evaluate the validity of the normalization of the CDR2
expression. All the three reference genes were highly sig-
nificantly correlated (r = 0.50–0.65, P \ 0.008–0.0002)
according to the Spearman rank correlation test (Graphpad
Prism).
Sequencing
CDR2 cDNA was sequenced from the 14 ovarian cancers.
The following primers for amplifying CDR2 were used:
293U20 50-CTA GAA GAC CCA GCC GAG AT-30,
659L19 50-TTG CAG GCA TTC AAT CGT T-30, 293u21
50-CTA GAA GAC CCA GCC GAG ATG-30, 975L21
50-CCT TTA ACA CGA GCC CAT ATT-30, 874U20
50-GCC CTG ATG AAG AGG AAA AT-30, 1370L20
50-GCT GTA CTG CGT GTC CAC TT-30, 1265U29
50-AGG GAG TGA CAT CGT GAA GG-30, and 1819L20
50-CCT CGT TGT ATG CAT TTG CT-30. We used one
tenth cDNA as a template for a PCR reaction using
Amplitaq Gold polymerase (www.appliedbiosystems.com).
cDNA was denaturated at 95C for 10 min followed by 35
PCR cycles (95C for 30 s, 55C for 30 s, and 72C for
60 s) and then held at 4C. The PCR product was purified
using Montage PCR Centrifugal Filter Devices according
to the manufacturer’s instructions (www.Millipore.com).
The PCR product was bidirectionally sequenced using a
Big Dye terminator 3.1 cycle sequencing kit according to
the manufacturer’s recommendation on an ABI 3700 DNA
Analyzer (www.appliedbiosystems.com). ChromasPro was
used to analyze the sequence files (www.softpedia.com),
BLAST for identifying the DNA sequence (www.ncbi.nml.
nih.gov), and Clustal W2 for aligning sequences
(www.ebi.ac.uk/Tools/clustalw2).
Immunoblot
We subjected the various extracts to a 10% SDS-PAGE
and performed western blotting. The following concentra-
tions were loaded to the gels: 10 lg of each cancer extract,
20 lg of the ovarian lysates according to the manufacturer
(www.prosci-inc.com), and 100 lg of the human cerebrum
and cerebellum extracts. The membranes were first incu-
bated with a 1:200 dilution of the anti-CDR2 monoclonal
antibody (sc-100320) and then with a goat anti-mouse
HRP antibody (sc-2005) diluted 1:1000, both antibodies
obtained from Santa Cruz Biotechnology, Inc. (www.scbt.
com). The reactions were developed by the ECL Plus
Western Blotting Detection system (RPN2132) (www.
healthcare.com) and then read using a Fuji-las 1000
luminescent image analyzer (www.fujifilm.com).
Immunohistochemistry
Intracellular localization of CDR2 was done in the ovarian,
lung, and cervical cancer cell lines. The cell lines were
grown and treated as previously described [10]. After fix-
ation and permeabilization, the cells were incubated with a
1:200 dilution of anti-CDR2 polyclonal antibody
(ab59566) or anti-CDR2 monoclonal antibody (sc-100320)
(www.abcam.com) and then with Alexa Fluor 488 goat
anti-rabbit antibody (A-11008) or with Alexa Fluor
488goat anti-mouse antibody (A-11001) (www.probes.
invitrogen.com), respectively, diluted 1:200 in blocking
solution. The slides were mounted with Vectashield with or
without DAPI (www.vectorlabs.com). Indirect immuno-
fluorescence was done using Zeiss LSM 510 Meta.
Absorption experiments were performed as previously
described [15] by diluting the anti-CDR2 polyclonal anti-
body to one titer below the highest dilution still producing
staining of HeLa cells. The antibody was incubated with
equal volume of the recombinant CDR2 protein overnight.
The antibody–antigen complex was spun down, and the
supernatant was applied to the cells as described and ana-
lyzed at a Zeiss Axiovert M200.
Intracellular localization of CDR2 was also done in
three ovarian cancer biopsies (from patients 1, 15, and 16
in Table 1) and in one colon cancer biopsy using the anti-
CDR2 polyclonal antibody (ab59566) (www.abcam.com)
diluted 1:400. The immunoperoxidase staining followed
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standard procedures at the Department of Pathology,
Haukeland University Hospital.
Results
Table 1 presents the histology and International Federation
of Gynecology and Obstetrics (FIGO) stage of the ovarian
cancers. Five of the 16 ovarian cancer patients had Yo
antibodies. The other 11 cancer patients were Yo antibody
negative.
Sequencing of CDR2 cDNA revealed no variants in the
14 ovarian cancers. For reference, we used CDR2 cDNA
sequence from human CDR2 (62 kDa), NM_001802
(www.ncbi.nlm.nih.gov).
Using RT-PCR, we found approximately similar
expression levels (1–2 fold differences) in the mRNA
CDR2 between the 14 ovarian cancers and in the other
normal human tissue controls—brain, heart, kidney, liver,
lung, trachea, mammary gland, prostate, skeletal muscle,
testis, and uterus—and in the human reference total RNA.
Immunoblot of the 14 human ovarian cancer extracts, as
well as from the human ovary tumor and human normal
ovary tissue lysates showed bands of approximately similar
intensity with a molecular weight of 62 kDa (Fig. 1a). The
reaction in immunoblot was stronger with ovarian cancer
cells compared to lung and neuroblastoma cells. A weak
band of 62 kDa was found in the cerebellar, but not in the
cerebrum extracts (Fig. 1b). We used recombinant CDR2
as positive control. This band also corresponded to 62 kDa,
whereas no binding of the monoclonal anti-CDR2 antibody
was found to the negative ITT lysate. There was no binding
of the secondary antibody alone to any of the extracts or
lysates.
The polyclonal anti-CDR2 antibody showed granular
staining mainly of the cytoplasm of the ovarian, lung,
and cervical cancer cell lines (Fig. 2a, b, and d).
Fig. 1 a Western blot shows CDR2 in four human ovarian cancer
extracts (1–4), in lysates of human ovarian cancer (5), and human
normal ovary tissue (6). b Western blot shows recombinant CDR2 as
positive control (1), CDR2 in cell lines of lung cancer (2), ovarian
cancer (3), neuroblastoma (4), and in human normal cerebellum (5),
but not in human normal cerebrum (6)
Fig. 2 Staining with polyclonal
antibody against CDR2 shows
granular green staining mainly
in the cytoplasm of cell lines of
ovarian cancer (a) and lung
cancer (b). DAPI stains the
nuclei blue. A similar granular
staining pattern was found in the
cell line of cervical cancer using
monoclonal antibody against
CDR2 (c) and polyclonal
antibody against CDR2 (d), but
the staining was almost
completely abolished after
preincubation of the polyclonal
antibody with recombinant
CDR2 (e)
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The monoclonal antibody against CDR2 showed a similar
staining pattern (Fig. 2c compared to d). Preabsorption of
the polyclonal antibody with recombinant CDR2 almost
completely abolished the staining (Fig. 2d compared to e).
The polyclonal anti-CDR2 antibody showed a nuclear and
cytoplasmic staining of cancer cells in ovarian and colon
biopsies. Staining was also present on normal stromal and
epithelial cells present in ovarian cancer. There was no
binding of the secondary antibody alone to any of the tissue
sections or cell slides (Fig. 3). The monoclonal anti-CDR2
antibody did not stain the tissue sections.
Discussion
This study provides further data on CDR2 in various
cancers and its relation to Yo antibodies. We found that
sequencing CDR2 cDNA from various human ovarian
cancers showed no variants that could involve possible
alternative transcription of the CDR2 gene. Whether
there are any variants in the CDR2 promoter region is
not known. However, mutations in another neuro-onco-
gene (HuD) have been demonstrated in lung neuroen-
docrine tumors [16], and variable levels of expression of
the HuD gene were previously reported in small-cell
lung cancer cell lines with different degrees of neuro-
endocrine differentiation [17]. It may, therefore, be
differences in the gene regulation between CDR2 and
HuD.
The human ovarian cancers and various normal human
tissues expressed approximately similar levels of CDR2
mRNA. This is in accordance with a previous study of
mouse tissue in which CDR2 mRNA was widely expressed
using Northern blot analysis [3].
Fig. 3 Ovarian and colon
cancer biopsies were stained
with polyclonal antibody
against CDR2. There was no
binding of the secondary
antibody alone to ovarian cancer
(a). The same ovarian cancer
from a patient with Yo
antibodies, but no PCD showed
CDR2 staining of cytoplasm
and nuclei of the cancer cells
(b). This biopsy also contained
normal ovarian tissue with
slight CDR2 staining of stromal
cells and strong CDR2 staining
of epithelial cell (c). Two other
ovarian cancers from patients
with PCD and Yo antibodies
showed nuclear CDR2 staining
of the cancer cells (d, e). Colon
cancer cells also expressed
nuclear and cytoplasmic CDR2
staining (f)
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We also found that the ovarian cancers expressed
approximately similar levels of CDR2 protein regardless of
histology or FIGO stage. However, the material has to be
larger to be certain if there are significant differences in
CDR2 mRNA or protein expression between histological
subtypes of ovarian cancer. Recent findings have suggested
that human papillary renal cell carcinoma expresses higher
CDR2 mRNA and protein levels than human clear-cell
renal carcinoma [9]. In our study, we also detected CDR2
protein in cell lines of lung, cervical and ovarian cancer
and neuroblastoma, as well as in colon cancer, indicating
that CDR2 protein is expressed in various cancers.
In a previous study, only 13 of 21 (62%) human ovarian
cancers (20 epithelial cancers and one stromal cancer)
expressed Yo protein using immunoblot of the cancer
lysates and serum from a PCD patient containing Yo
antibodies [4]. Our results, however, showed that CDR2
was present in all 16 ovarian cancers studied. The speci-
ficity and sensitivity of the patient Yo serum used in the
previous study [4] and the monoclonal and polyclonal anti-
CDR2 antibodies used in this study are probably different,
which could explain the difference in the results. Based on
our results, we suggest that CDR2 translation occurs in all
ovarian cancers, but larger studies are needed to confirm
this. Our results are in accordance with findings in small-
cell lung cancer, where all cancers expressed the parane-
oplastic antigen HuD [18]. This was also true for CDR2 in
papillary renal cell carcinoma, but in clear-cell renal car-
cinoma about 1% was not stained for CDR2 [9].
We found by immunoblot that CDR2 was expressed
with higher intensity in ovarian, than in lung cancer cells,
but immunofluorescence studies of ovarian, cervical, and
lung cancer cell lines revealed approximately similar
CDR2 granular staining which was mainly localized to the
cytoplasm. A similar staining pattern has recently also been
demonstrated in cervical cancer cells, and the results fur-
ther showed that CDR2 was colocalized with c-myc during
mitosis [10]. However, in tissue sections of ovarian and
colon cancers we found both nuclear and cytoplasmic
CDR2 staining. The CDR2 staining was also present in
ovarian cancers from patients with or without PCD.
We found that CDR2 was not only present in various
cancers, but also in normal ovary tissue. This is in accor-
dance with results from the Human Protein Atlas where
CDR2 has been reported in normal ovary follicle and
stromal cells (www.proteinatlas.org). However, it contrasts
previous observations where Yo protein was not detected
by immunoblot of normal ovary lysate using serum from a
PCD patient [4], but the explanation for the different
results may again be the specificity and sensitivity of the
antibodies used.
We have previously reported that Yo antibodies are not
related to ovarian cancer histology or FIGO stage [12]. The
present results indicate that there is no direct association
between CDR2 cDNA sequence, mRNA, or protein level
and Yo antibodies. Unfortunately, we did not have more
Yo positive sera available from patients with correspond-
ing ovary cancers to be studied as outlined above. How-
ever, we also found CDR2 in ovary cancers from patients
with and without PCD, in various other cancers, as well as
in normal ovary tissue.
Our findings, therefore, suggest that Yo antibody syn-
thesis and development of PCD is not only related to the
expression of CDR2 alone, but also to immune dysregu-
lations, such as antigen presentation and T and B cell co-
operation. This is supported by recent findings that specific
disease-associated HLA class II alleles [19], as well as
dysfunction of regulatory T cells [20] may play a role in the
pathogenesis of paraneoplastic neurological syndromes.
Taken together, the results further strengthen the hypoth-
esis that paraneoplastic neurological syndromes are auto-
immune diseases.
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